Efficacy, Tolerability, and Safety of Oxybutynin Chloride in Pediatric Neurogenic Bladder With Spinal Dysraphism: A Retrospective, Multicenter, Observational Study
| العنوان: | Efficacy, Tolerability, and Safety of Oxybutynin Chloride in Pediatric Neurogenic Bladder With Spinal Dysraphism: A Retrospective, Multicenter, Observational Study |
|---|---|
| المؤلفون: | Kwanjin Park, Sang Hoon Song, Sang Won Han, Kyoung Rok Kim, Minki Baek, Jung Hoon Lee, Kun Suk Kim, Yong Seung Lee |
| المصدر: | Korean Journal of Urology |
| بيانات النشر: | The Korean Urological Association, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Constipation, Adolescent, Muscarinic Antagonists, Oxybutynin Chloride, medicine, Humans, Neurogenic urinary bladder, Urinary Bladder, Neurogenic, Child, Oxybutynin, Adverse effect, Spinal Dysraphism, Neurogenic bladder dysfunction, Retrospective Studies, Pediatric Urology, business.industry, Infant, Newborn, Infant, Retrospective cohort study, medicine.disease, Pediatric urology, Treatment Outcome, Tolerability, Child, Preschool, Anesthesia, Drug Evaluation, Mandelic Acids, Urological Agents, Female, Original Article, medicine.symptom, business, medicine.drug |
| الوصف: | Purpose Anticholinergics are a key element in treating neurogenic detrusor overactivity, but only limited data are available in the pediatric population, thus limiting the application to children even for oxybutynin chloride (OC), a prototype drug. This retrospective study was designed to provide data regarding the efficacy, tolerability, and safety of OC in the pediatric population (0-15 years old) with spinal dysraphism (SD). Materials and methods Records relevant to OC use for neurogenic bladder were gathered and scrutinized from four specialized clinics for pediatric urology. The primary efficacy outcomes were maximal cystometric capacity (MCC) and end filling pressure (EFP). Data on tolerability, compliance, and adverse events (AEs) were also analyzed. Results Of the 121 patient records analyzed, 41 patients (34%) received OC at less than 5 years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median treatment duration was 19 months (range, 0.3-111 months). Significant improvement of both primary efficacy outcomes was noted following OC treatment. MCC increased about 8% even after adjustment for age-related increases in MCC. Likewise, mean EFP was reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance above 70%, and approximately 50% of patients used OC for more than 1 year. No serious AEs were reported; constipation and facial flushing consisted of the major AEs. Conclusions OC is safe and efficacious in treating pediatric neurogenic bladder associated with SD. The drug is also tolerable and the safety profile suggests that adjustment of dosage for age may not be strictly observed. |
| تدمد: | 2005-6745 2005-6737 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50ff0c8aa06f46c9f0a4f8e30a85c4e5Test https://doi.org/10.4111/kju.2014.55.12.828Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....50ff0c8aa06f46c9f0a4f8e30a85c4e5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20056745 20056737 |
|---|